Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
Chemotherapy with or without radiation remains the first choice for most cancers. However, intolerant side effects and conventional drug resistance restrict actual clinical efficacy. Curaxin CBL0137 is designed to regulate p53 and nuclear factor-κB simultaneously and to prevent the resistance caused...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2018-12-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/article/10.3389/fonc.2018.00598/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|